Wednesday's news centered on Novo Nordisk and on commentary from the Morgan Stanley 24th Annual Global Healthcare Conference. Novo Nordisk announced a collaboration with Anthropic to test Claude Science in specific research and development workflows, and separately previewed 44 abstracts for EASD 2026 in Milan, including real-world Wegovy pill data from the OCTANE study. At the Morgan Stanley conference, Zealand Pharma CEO Adam Steensberg restated the company's Metabolic Frontier 2030 goal of five marketed products and 10 clinical programs by 2030, with petrelintide, its amylin analog partnered with Roche, at the center. Circle Pharma closed an oversubscribed $92.5 million Series E, with Eli Lilly among the investors, to take its oral macrocyclic cyclin D1 inhibitor CID-165 into the clinic in the first quarter of 2027. Vera Therapeutics reported that TRUTAKNA cut the risk of composite kidney disease progression by 76% over 104 weeks in the 428-patient ORIGIN 3 trial, and Diasome Pharmaceuticals named a new chief medical officer as it prepares HDV-Insulin for Phase 3.
Correction (September 23, 2026): This digest was revised to remove claims that could not be traced to a primary source and to replace general source links with specific ones. Corrected facts: the Roche–Zealand petrelintide agreement was announced in March 2025, not April 2026; Filspari (sparsentan) is not an Otsuka product, and that competitor reference was removed. A reference to a Roche Pharma Day on September 28, Phase 2b OPTI-2 hypoglycemia figures, and a comparison of the Novo–Anthropic deal to other pharma AI agreements were removed because the cited sources do not support them.